Studies of hepatocellular carcinoma have shown that IL-17E activates the NFκB and Jak/STAT3 signaling pathways in cancer stem cells, thus resulting in tumor growth and progression and suggesting that IL-17E/IL-17RB may be a therapeutic target in the treatment of this disease [40]. The gene discussed is NFKB1; the disease is cancer.